You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

MASS. MOVERS

Amag results expected to come up short

ISTOCKPHOTO.COM

Continue reading below

Amag Pharmaceuticals Inc. slumped on preliminary fourth-quarter revenue of between $14.3 million and $15 million, lower than the $16 million analysts had estimated. The Lexington company put itself up for sale late last year after lackluster revenue for its anemia drug and a failed merger bid. It received approval for Feraheme from Canadian regulators in December. Amag said it expects fourth-quarter operating costs and expenses of $38 million to $43 million, including restructuring costs and a $2 million termination fee to Allos Therapeutics.

Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com